Compare REAL & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REAL | PRQR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 166.5M |
| IPO Year | 2019 | 2014 |
| Metric | REAL | PRQR |
|---|---|---|
| Price | $9.20 | $1.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $17.00 | $7.25 |
| AVG Volume (30 Days) | ★ 3.9M | 672.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $692,845,000.00 | N/A |
| Revenue This Year | $14.30 | N/A |
| Revenue Next Year | $10.15 | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.38 | N/A |
| 52 Week Low | $4.71 | $1.33 |
| 52 Week High | $17.39 | $3.10 |
| Indicator | REAL | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 38.92 | 46.33 |
| Support Level | $8.05 | $1.51 |
| Resistance Level | $11.48 | $1.58 |
| Average True Range (ATR) | 0.69 | 0.12 |
| MACD | -0.21 | -0.01 |
| Stochastic Oscillator | 10.64 | 42.42 |
The RealReal Inc is an online marketplace for authenticated, resale luxury goods, providing an end-to-end service that unlocks supply and creates a trusted, curated marketplace for buyers globally. Since its inception, the company has cultivated a loyal and engaged consignor and buyer base through continuous investment in its technology platform, logistics infrastructure, brand and people. It offers a wide selection of authenticated, mainly pre-owned luxury goods bearing the brands of thousands of luxury and premium designers, including Cartier, Chanel, Christian Dior, Gucci, Hermes, Louis Vuitton and Rolex. The company offers products across women's fashion, men's fashion, jewelry, and watches, promoting the recirculation of luxury goods and contributing to a more sustainable world.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.